Literature DB >> 15831674

Letrozole-, anastrozole-, and tamoxifen-responsive genes in MCF-7aro cells: a microarray approach.

Toru Itoh1, Kim Karlsberg, Ikuko Kijima, Yate-Ching Yuan, David Smith, Jingjing Ye, Shiuan Chen.   

Abstract

Antiestrogens and aromatase inhibitors are important drugs in the treatment of estrogen-dependent breast cancer. To investigate the effects of these drugs on gene expression in breast cancer cells, we treated estrogen receptor-positive MCF-7 cells stably transfected with the aromatase gene (known as MCF-7aro cells) with testosterone, 17 beta-estradiol, two aromatase inhibitors (letrozole and anastrozole), and an antiestrogen (tamoxifen). We found that testosterone or 17 beta-estradiol induced the proliferation of MCF-7aro cells at a rate six times faster than the untreated cells. In addition, the testosterone-induced proliferation of MCF-7aro cells was effectively suppressed by letrozole, anastrozole, or tamoxifen. Microarray analyses on Affymetrix Human Genome U133A GeneChips (Affymetrix, Santa Clara, CA) were carried out using total RNA isolated from the control and treated cells. At the false discovery rate of 0.05 and a minimum fold-change criteria of 1.5, 104 genes were identified that were up-regulated and 109 genes were identified that were down-regulated by both androgen and estrogen. More than 50% of these hormone-regulated genes were counter-regulated by all three inhibitors and >90% were counter-regulated by at least one of the inhibitors. Comparing the effect of each inhibitor on gene expression, we observed that letrozole and anastrozole are more similar in terms of the genes they affect compared with treatment with tamoxifen. To validate the gene expression profiles identified from microarray analyses, the expression patterns of 13 representative genes were examined by Northern analysis. Finally, the genes identified as statistically significant were classified based on their expression patterns and biological function/pathways. The results of this study provide us with a better understanding of the actions of both aromatase inhibitors and antiestrogens at the molecular level. We believe that the results of this study serve as the first step in identifying unique expression patterns following drug treatment, and that this will ultimately be useful in customizing patient treatment strategies for hormone-dependent breast cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15831674     DOI: 10.1158/1541-7786.MCR-04-0122

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  29 in total

1.  Oestrogen inhibition reverses pulmonary arterial hypertension and associated metabolic defects.

Authors:  Xinping Chen; Eric D Austin; Megha Talati; Joshua P Fessel; Eric H Farber-Eger; Evan L Brittain; Anna R Hemnes; James E Loyd; James West
Journal:  Eur Respir J       Date:  2017-08-03       Impact factor: 16.671

2.  Proteomic signatures of acquired letrozole resistance in breast cancer: suppressed estrogen signaling and increased cell motility and invasiveness.

Authors:  Syreeta L Tilghman; Ian Townley; Qiu Zhong; Patrick P Carriere; Jin Zou; Shawn D Llopis; Lynez C Preyan; Christopher C Williams; Elena Skripnikova; Melyssa R Bratton; Qiang Zhang; Guangdi Wang
Journal:  Mol Cell Proteomics       Date:  2013-05-23       Impact factor: 5.911

Review 3.  Functional genomics of endothelial cells treated with anti-angiogenic or angiopreventive drugs.

Authors:  Adriana Albini; Stefano Indraccolo; Douglas M Noonan; Ulrich Pfeffer
Journal:  Clin Exp Metastasis       Date:  2010-04-10       Impact factor: 5.150

Review 4.  What do we know about the mechanisms of aromatase inhibitor resistance?

Authors:  Shiuan Chen; Selma Masri; Xin Wang; Sheryl Phung; Yate-Ching Yuan; Xiwei Wu
Journal:  J Steroid Biochem Mol Biol       Date:  2006-10-19       Impact factor: 4.292

Review 5.  Pathways to tamoxifen resistance.

Authors:  Rebecca B Riggins; Randy S Schrecengost; Michael S Guerrero; Amy H Bouton
Journal:  Cancer Lett       Date:  2007-05-01       Impact factor: 8.679

6.  Regulation of aryl hydrocarbon receptor function by selective estrogen receptor modulators.

Authors:  Carolyn D DuSell; Erik R Nelson; Bryan M Wittmann; Jackie A Fretz; Dmitri Kazmin; Russell S Thomas; J Wesley Pike; Donald P McDonnell
Journal:  Mol Endocrinol       Date:  2009-11-09

7.  Characterization of the weak estrogen receptor alpha agonistic activity of exemestane.

Authors:  Selma Masri; Ki Lui; Sheryl Phung; Jingjing Ye; Dujin Zhou; Xin Wang; Shiuan Chen
Journal:  Breast Cancer Res Treat       Date:  2008-08-03       Impact factor: 4.872

8.  Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole.

Authors:  William R Miller; Alexey Larionov
Journal:  Breast Cancer Res       Date:  2010-07-20       Impact factor: 6.466

9.  The Gene expression Grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trial.

Authors:  Christine Desmedt; Anita Giobbie-Hurder; Patrick Neven; Robert Paridaens; Marie-Rose Christiaens; Ann Smeets; Françoise Lallemand; Benjamin Haibe-Kains; Giuseppe Viale; Richard D Gelber; Martine Piccart; Christos Sotiriou
Journal:  BMC Med Genomics       Date:  2009-07-02       Impact factor: 3.063

10.  Reverse phase high performance liquid chromatographic method for the analysis of letrozole in pharmaceutical dosage forms.

Authors:  T K Laha; R K Patnaik; S Sen
Journal:  Indian J Pharm Sci       Date:  2008 May-Jun       Impact factor: 0.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.